Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study
Allergology International · 2026
DOI: 10.1016/j.alit.2025.09.002 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Allergology International, 2026. Verfasst von Yoko Kataoka und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Osaka Habikino Medical Center, Habikino, Japan. Electronic address: kataokay@ra.opho.jp. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Adrenal Cortex Hormones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi KK.
Abstract (Originalsprache)
BACKGROUND: Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension (OLE) of a phase 3 study that assessed dupilumab in Japanese patients aged ≥6 months to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Osaka Habikino Medical Center, Habikino, Japan. Electronic address: kataokay@ra.opho.jp.
- Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Sagamihara, Japan.
- Department of Dermatology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Clinical Research, NHO Mie National Hospital, Tsu, Japan.
- Sanofi, Bridgewater, NJ, USA.
- Immunology Medical, Sanofi K.K., Tokyo, Japan.
Förderung
- Sanofi KK
Zitieren
APA
Kataoka, Y., Ebisawa, M., Tanaka, A., Nagao, M., Laws, E., Nawata, H., Arima, K., Watanabe, D., Lu, X., Maloney, J., Dubost-Brama, A., Bansal, A., & Yahata, K. (2026). Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study. Allergology International. https://doi.org/10.1016/j.alit.2025.09.002
Vancouver
Kataoka Y, Ebisawa M, Tanaka A, Nagao M, Laws E, Nawata H, et al. Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study. Allergology International. 2026. doi:10.1016/j.alit.2025.09.002
BibTeX
@article{Kataoka2026,
author = {Kataoka, Yoko and Ebisawa, Motohiro and Tanaka, Akio and Nagao, Mizuho and Laws, Elizabeth and Nawata, Hisakatsu and Arima, Kazuhiko and Watanabe, Daisuke and Lu, Xin and Maloney, Jennifer and Dubost-Brama, Ariane and Bansal, Ashish and Yahata, Kenji},
title = {Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study},
journal = {Allergology International},
year = {2026},
doi = {10.1016/j.alit.2025.09.002}
}
EUVIMED